Celerion And KDDF Enter Research Collaboration In South Korea

Early clinical research firm Celerion and South Korean government-funded Korean Drug Development Fund (KDFF) announced that they have entered into a collaboration to strengthen early phase clinical research in South Korea. The partnership aims to improve drug development efforts and to support the emerging drug discovery and development industry in the nation.

According to a Memorandum of Understanding (MOU), KDDF-funded companies will gain access to Celerion’s resources in early clinical research and bioanalysis, including global footprint of external partner sites. The partnership will enable all parties involved to share knowledge that will aid in the development of new and efficient ways to bring Korean drug discoveries into the global market.

Susan Thornton, President and CEO of Celerion, said, “We are delighted to collaborate with KDDF, and to provide early clinical research expertise to support and strengthen the emerging pharmaceutical industry in South Korea. Our agreement with KDDF is further evidence of Celerion’s enthusiasm and commitment to contributing to the growth of South Korea’s biomedical research industry.”

“The KDDF is very happy to have established a partnership with Celerion. This collaboration is aligned to our vision to build effective partnerships between government, industry and academia. Together with Celerion, KDDF will be able to provide professional consulting services to the Korean research communities to advance the research activities and promote important innovation,” said Dongho Lee, CEO of KDDF.

Celerion will also support all KDDF programs, including the recently announced business expansion inside the Biomedical Research Institute at Seoul National University Hospital (SNUH), in South Korea.

Celerion specializes in delivering Applied Translational Medicine and, in this partnership, will be working to provide information gleaned from its research discoveries. The company provides management and analysis of First-in-Human, clinical Proof-of-Concept, and NDA-enabling clinical pharmacology studies.

The KDDF, established in 2011, manages drug development projects and provides grant support to advance milestone-based research initiatives.